Castle Biosciences Inc. (CSTL) Tops Q1 EPS by 23c ; Offers Guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q1 EPS of ($0.09), $0.23 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $73 million versus the consensus estimate of $65.79 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2024 revenue of $255-265 million, versus the consensus of $237.6 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c